Origo Biopharma is a Spanish pharmaceutical company founded in 2017 by entrepreneurs with extensive experience in discovery and development of pharmaceuticals.
Our know-how ranges from early medicinal chemistry stages to successful execution of late stage clinical trials leading to registration of novel pharmaceutical products.
We specialize on research and development of small molecules that address health disorders related to TGF-β signaling dysfunction, among these fibrosis and cancer.
The discovery and development of next generation therapeutic products for treatment of severe diseases linked to TGF-β.
To improve life quality and ultimately, contribute to the curing of people suffering from devastating medical conditions.